News
CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...
The 61-year-old man received a new kidney from a deceased donor after being diagnosed with “nephrosclerosis-related end-stage ...
13d
Zacks.com on MSNCHMP Backs NVO's Ozempic EU Label Update for Cardiovascular IndicationCHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients ...
Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
5d
Irish Independent on MSNAsk the doctor: I have a BMI of 31 and high cholesterol. Should I ask my GP for Ozempic?Question: I am a woman with a BMI of 31 and have recently been put on statins for high cholesterol. I have also been told ...
GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...
Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a ...
Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities Published ...
Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also ...
Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure ...
As a mass rollout of weight loss injections begins across the NHS, with GPs able to prescribe Mounjaro for the first time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results